文献速递慢性肾脏病血液净化与透析

卡格列净对基线eGFR<30 ml/min/1.73 m²患者的影响:CREDENCE随机试验亚组分析

Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2020-11-19

CREDENCE试验事后分析纳入随机分组时eGFR<30 ml/min/1.73 m²的174例2型糖尿病合并CKD患者(占4%),评估卡格列净的疗效与安全性。结果显示卡格列净减缓eGFR下降,肾脏、心血管及死亡结局与eGFR≥30者一致,未增加AKI。

要点

  • 卡格列净使eGFR<30患者eGFR年下降斜率减缓2.54 ml/min/1.73 m²。
  • 肾脏、心血管和死亡结局与eGFR≥30患者一致,交互作用不显著。
  • 卡格列净未增加肾脏相关不良事件或AKI风险。

核心结论

  • 卡格列净可减缓eGFR<30 ml/min/1.73 m²患者的肾脏病进展,且不增加AKI。

研究设计与样本

  • CREDENCE试验事后分析,纳入随机分组时eGFR<30 ml/min/1.73 m²的174例患者(占4401例的4%),平均eGFR 26 ml/min/1.73 m²。

主要发现

  • 第3至130周,卡格列净组与安慰剂组eGFR平均斜率分别为-1.30和-3.83 ml/min/1.73 m²/年,差异-2.54 ml/min/1.73 m²/年(95%CI 0.90至4.17)。
  • eGFR<30患者肾衰竭风险比0.67(95%CI 0.35至1.27),与eGFR≥30者(HR 0.70,95%CI 0.54至0.91)相似,交互作用P=0.80。
  • 肾脏、心血管及死亡结局在eGFR<30与≥30组间一致(所有交互作用P>0.20)。
  • 肾脏相关不良事件或AKI发生率在eGFR<30与≥30组间无差异(所有交互作用P>0.12)。

临床怎么用

  • 对于eGFR<30 ml/min/1.73 m²的2型糖尿病合并CKD患者,可考虑使用卡格列净以减缓肾功能下降。

局限性

  • 为事后亚组分析,eGFR<30亚组样本量较小(174例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial demonstrated that the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduced the risk of kidney failure and cardiovascular events in participants with type 2 diabetes mellitus and CKD. Little is known about the use of SGLT2 inhibitors in patients with eGFR <30 ml/min per 1.73 m2. The participants in the CREDENCE study had type 2 diabetes mellitus, a urinary albumin-creatinine ratio >300-5000 mg/g, and an eGFR of 30 to <90 ml/min per 1.73 m2 at screening. This post hoc analysis evaluated participants with eGFR <30 ml/min per 1.73 m2 at randomization. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Effects of eGFR slope through week 130 were analyzed using a piecewise, linear, mixed-effects model. Efficacy was analyzed in the intention-to-treat population, on the basis of Cox proportional hazard models, and safety was analyzed in the on-treatment population. At randomization (an average of 29 days after screening), 174 of 4401 (4%) participants had an eGFR <30 ml/min per 1.73 m2 (mean [SD] eGFR, 26 [3] ml/min per 1.73 m2). RESULTS: From weeks 3 to 130, there was a 66% difference in the mean rate of eGFR decline with canagliflozin versus placebo (mean slopes, -1.30 versus -3.83 ml/min per 1.73 m2 per year; difference, -2.54 ml/min per 1.73 m2 per year; 95% confidence interval [CI], 0.90 to 4.17). Effects of canagliflozin on kidney, cardiovascular, and mortality outcomes were consistent for those with eGFR <30 and ≥30 ml/min per 1.73 m2 (all P interaction >0.20). The estimate for kidney failure in participants with eGFR <30 ml/min per 1.73 m2 (hazard ratio, 0.67; 95% CI, 0.35 to 1.27) was similar to those with eGFR ≥30 ml/min per 1.73 m2 (hazard ratio, 0.70; 95% CI, 0.54 to 0.91; P interaction=0.80). There was no imbalance in the rate of kidney-related adverse events or AKI associated with canagliflozin between participants with eGFR <30 and ≥30 ml/min per 1.73 m2 (all P interaction >0.12). CONCLUSIONS: This post hoc analysis suggests canagliflozin slowed progression of kidney disease, without increasing AKI, even in participants with eGFR <30 ml/min per 1.73 m2.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Bakris G, Oshima M, Mahaffey KW, et al. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. Clin J Am Soc Nephrol. 2020. PMID: 33214158. doi:10.2215/CJN.10140620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。